TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:11
Armata Pharmaceuticals Inc. ( ARMP ) https://www.armatapharma.com
4.04USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
ARMP
160.65%
SPY
32.74%
-17.38%
ARMP
SPY
92.93%
-4.13%
ARMP
SPY
224.41%
-99.90%
ARMP
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
135.10
159.64
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.16
60.38
-4.21
-53.81
0.00
-4.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.3499
18.59
-54.09
1.63
Other Earnings and Cash Flow Stats:
Armata Pharmaceuticals Inc. ( ARMP ) Net Income TTM ($MM) is -67.70
Armata Pharmaceuticals Inc. ( ARMP ) Operating Income TTM ($MM) is -40.63
Armata Pharmaceuticals Inc. ( ARMP ) Owners' Earnings Annual ($MM) is 81.72
Armata Pharmaceuticals Inc. ( ARMP ) Current Price to Owners' Earnings ratio is 1.79
Armata Pharmaceuticals Inc. ( ARMP ) EBITDA TTM ($MM) is -33.39
Armata Pharmaceuticals Inc. ( ARMP ) EBITDA Margin is 0.00%
Capital Allocation:
Armata Pharmaceuticals Inc. ( ARMP ) has paid 0.00 dividends per share and bought back -1.828808 million shares in the past 12 months
Armata Pharmaceuticals Inc. ( ARMP ) has reduced its debt by 10.751 million USD in the last 12 months
Capital Structure:
Armata Pharmaceuticals Inc. ( ARMP ) Interest-bearing Debt ($MM) as of last quarter is 38
Armata Pharmaceuticals Inc. ( ARMP ) Annual Working Capital Investments ($MM) are -1
Armata Pharmaceuticals Inc. ( ARMP ) Book Value ($MM) as of last quarter is -33
Armata Pharmaceuticals Inc. ( ARMP ) Debt/Capital as of last quarter is -119%
Other Balance Sheet Stats:
Armata Pharmaceuticals Inc. ( ARMP ) has 13 million in cash on hand as of last quarter
Armata Pharmaceuticals Inc. ( ARMP ) has 16 million of liabilities due within 12 months, and long term debt 98 as of last quarter
Armata Pharmaceuticals Inc. ( ARMP ) has 36 common shares outstanding as of last quarter
Armata Pharmaceuticals Inc. ( ARMP ) has 0 million USD of preferred stock value
Academic Scores:
Armata Pharmaceuticals Inc. ( ARMP ) Altman Z-Score is -5.14 as of last quarter
Armata Pharmaceuticals Inc. ( ARMP ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Armata Pharmaceuticals Inc. ( ARMP ) largest shareholder is STIFEL FINANCIAL CORP owning 19729 shares at 0.08 ($MM) value
Innoviva Strategic Opportunities LLC(an insider) Bought 0 shares of Armata Pharmaceuticals Inc. ( ARMP ) for the amount of $0.00 on 2022-03-31
69.60% of Armata Pharmaceuticals Inc. ( ARMP ) is held by insiders, and 3.58% is held by institutions
Armata Pharmaceuticals Inc. ( ARMP ) went public on 2011-03-09
Other Armata Pharmaceuticals Inc. ( ARMP ) financial metrics:
FCF:-55.35
Unlevered Free Cash Flow:-16.00
EPS:-3.45
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:388.72
Beta:1.63
Buffet's Owners Earnings:81.72
Price to Owner's Earnings:1.79
About Armata Pharmaceuticals Inc. ( ARMP ) :
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.